Clinical trials: KRAS Gene Mutation

KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

• Active, not recruiting
• Age: All ages
• Phase 2
• Injection or infusion
• Results posted

This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back.

Conditions

KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Trial name

NCT02642042

Testing

Docetaxel, Laboratory Biomarker Analysis, Trametinib

Where

596 sites in United States

Volunteers

60 people

Sponsor

National Cancer Institute (NCI)